Organization Profile

Related Organization(s)

You just read:

Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)

News provided by

Eli Lilly and Company

Jun 09, 2016, 06:45 ET